908. Whole Genome-Based Epidemiology and Outbreak Investigation
Session: Symposium: Metagenomic-Based Infectious Disease Diagnostics
Friday, October 5, 2018: 9:35 AM
Room: S 214-216
Dag Harmsen, MD, Faculty of Medicine, University of Münster, Münster, Germany

Dr. Dag Harmsen is an MD specialized in Clinical Microbiology and Infectious Diseases Epidemiology. Since 2004 he holds a professorship at the Medical Faculty of the University Münster, Germany. His scientific interests focus around molecular diagnostics, epidemiology, and phylogeny of micro-organisms. He published the world-wide first study that applied the Bruker MALDI ToF MS system in microbiological diagnostics (JCM 2008; 46:1946). More recently he earned some recognition as an early Ion Torrent PGM adopter during the 2011 German STEC O104:H4 outbreak (PLoS ONE 2011; 6:e22751). More recently he published a highly noted NGS benchtop machine comparison (Nat Biotechnol 2013; 31:294). However, he is best known for delivering for more than 15 years popular applied microbiology bioinformatics solutions - like spa-typing for MRSA (JCM 2003; 41:5442) or the MIRU-VNTR service for M. tuberculosis typing (Nucleic Acids Res 2010; 38:W326). From 2000 until 2002 he was head of R&D of the diagnostics division of Creatogen AG, Germany. Next to the development of In vitro Diagnostics (IvD) he was mainly dealing with patent issues and with CE-marking and FDA 510K clearance of IvD products. Dr. Harmsen is also co-founder (2003), shareholder, and co-managing director of Ridom GmbH (Münster, Germany). Ridom develops bioinformatic software for clinical and public health microbiology sequence analysis. From 2005 until 2014 he was a member of the Executive Board of the 'International Committee on Systematics of Prokaryotes' (ICSP) of the International Union of Microbiological Societies (IUMS). From 2007 until July 2012 he served in the 'Professional Development Committee' of the American Society for Microbiology (ASM). Since October 2012 he is the ASM Ambassador in Germany. Finally, Dr. Harmsen is a technical advisor for genotyping and NGS of ECDC and EFSA.


Disclosures:

D. Harmsen, Ridom GmbH: Shareholder , Salary .

<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.